ARCHIVES

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

This article is from The Cancer Letter archive.

Vol. 37 No. 32 | August 12, 2011

Download PDF Visit The Full Archive

Related Articles

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

Gleevec Decreases Recurrence Of Gastrointestinal Tumor

April 27, 2007

Duke Scientists Develop 3D Mammography Using CT

February 24, 2006

Eight Firms Join AACR As Sustaining Members

April 25, 1997

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Guest Editorial: The Walue of Quality of Life Data In Judging Patient Benefit: experts Respond To ODAC

September 3, 1999